Literature DB >> 8616553

Concentrations of methacholine for bronchial responsiveness according to symptoms, smoking and immunoglobulin E in a population-based study in Spain. Spanish Group of the European Asthma Study.

J Sunyer1, A Muñoz.   

Abstract

To assess the simultaneous effects of symptoms related to asthma, smoking, and Immunoglobulin E (IgE) on the concentrations of methacholine at which different individuals fall below 80% the FEV1 values obtained with saline, we used parametric survival methods that fit the dose-response nature of bronchial responsiveness (BR). A general population-based sample of 1,615 adults (aged 20 to 44 yr) from five cities in Spain participating in the European Community Respiratory Health Survey was studied. The total number of subjects whose FEV1 values dropped below 80% was 237 (14.7%). We found that individuals with symptoms related to asthma, whether they were smokers or nonsmokers, responded at lower concentrations of methacholine than individuals without symptoms. The greatest decrease in the concentrations of methacholine at which different percentages of individuals responded was due to symptoms among the nonsmokers (relative percentiles ranging from 0.53 to 0.76, and a 90% confidence band not containing a value one). Among individuals without symptoms, smokers responded at moderately but significantly lower concentrations than nonsmokers, whereas an apparent protective effect of smoking was seen in symptomatic individuals, owing in part to a self-selection bias. The higher the concentration of IgE, the lower were the concentrations of methacholine needed to obtain a given level of BR. Moreover, the magnitude of the decrease in methacholine concentrations leading to a response was constant over all percentages of individuals responding. The analytical methods used in the study permit the incorporation of complexities in the relationships between BR and symptoms, smoking, and IgE, and are generally applicable to situations in which a dose-response relationship occurs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616553     DOI: 10.1164/ajrccm.153.4.8616553

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

Review 1.  Methodology of bronchial responsiveness.

Authors:  S Chinn
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

2.  Airway hyperresponsiveness in children with sickle cell anemia.

Authors:  Joshua J Field; Janet Stocks; Fenella J Kirkham; Carol L Rosen; Dennis J Dietzen; Trisha Semon; Jane Kirkby; Pamela Bates; Sinziana Seicean; Michael R DeBaun; Susan Redline; Robert C Strunk
Journal:  Chest       Date:  2010-08-19       Impact factor: 9.410

3.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.

Authors:  J Corne; R Djukanovic; L Thomas; J Warner; L Botta; B Grandordy; D Gygax; C Heusser; F Patalano; W Richardson; E Kilchherr; T Staehelin; F Davis; W Gordon; L Sun; R Liou; G Wang; T W Chang; S Holgate
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  Smoking and bronchial responsiveness in nonatopic and atopic young adults. Spanish Group of the European Study of Asthma.

Authors:  J Sunyer; J M Antó; M Kogevinas; J B Soriano; A Tobias; A Muñoz
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

Review 5.  Cigaret smoking and the lung.

Authors:  S Murin; J Hilbert; S J Reilly
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 10.817

6.  Asthma, chronic bronchitis, and exposure to irritant agents in occupational domestic cleaning: a nested case-control study.

Authors:  M Medina-Ramón; J P Zock; M Kogevinas; J Sunyer; Y Torralba; A Borrell; F Burgos; J M Antó
Journal:  Occup Environ Med       Date:  2005-09       Impact factor: 4.402

7.  Targeted IgE Therapy for Patients With Moderate to Severe Asthma.

Authors:  Bradley E Chipps; Patricia L Marshik
Journal:  Biotechnol Healthc       Date:  2004-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.